Pigment International

REVIEW ARTICLE
Year
: 2021  |  Volume : 8  |  Issue : 1  |  Page : 8--13

Use of immunosuppressants in vitiligo during COVID-19 pandemic: a quick review


Hitaishi Mehta1, KT Soufila1, Sheetanshu Kumar1, Rashmi Sarkar2, Muthu Sendhil Kumaran1 
1 Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India
2 Department of Dermatology, LHMC and Associated KSCH and SSK Hospital, New Delhi, India

Correspondence Address:
Muthu Sendhil Kumaran
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012
India

Owing to the recent coronavirus (COVID-19) pandemic, there is a concern regarding the use of systemic immunosuppressive agents. There are no guidelines at present regarding the use of immunosuppressants. The main aim at this time should be to keep the dermatoses under control without exposing the patient to increased risk of infection and the consequent morbidity. In vitiligo, immunosuppressive agents are utilized in stabilization of progressive disease. An informed decision regarding the use of immunosuppressive agents can be made only after understanding the immune response to coronavirus, reviewing the mechanism of action of drug and evidence from previous studies on risk of infection. This review briefly discusses the mechanism of action and the safety data of various immunosuppressants used in vitiligo.


How to cite this article:
Mehta H, Soufila K, Kumar S, Sarkar R, Kumaran MS. Use of immunosuppressants in vitiligo during COVID-19 pandemic: a quick review.Pigment Int 2021;8:8-13


How to cite this URL:
Mehta H, Soufila K, Kumar S, Sarkar R, Kumaran MS. Use of immunosuppressants in vitiligo during COVID-19 pandemic: a quick review. Pigment Int [serial online] 2021 [cited 2021 Apr 14 ];8:8-13
Available from: https://www.pigmentinternational.com/article.asp?issn=2349-5847;year=2021;volume=8;issue=1;spage=8;epage=13;aulast=Mehta;type=0